Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ganciclovir
Drug ID BADD_D01003
Description An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Indications and Usage For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
Marketing Status approved; investigational
ATC Code J05AB06; S01AD09
DrugBank ID DB01004
KEGG ID D00333
MeSH ID D015774
PubChem ID 135398740
TTD Drug ID D05ARP
NDC Product Code 12806-6941; 51754-2500; 12869-803; 59651-108; 24208-535; 42023-173
UNII P9G3CKZ4P5
Synonyms Ganciclovir | Gancyclovir | BW-759 | Ganciclovir Sodium | Ganciclovir, Monosodium Salt | RS-21592 | BIOLF-62 | Cytovene
Chemical Information
Molecular Formula C9H13N5O4
CAS Registry Number 82410-32-0
SMILES C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypomagnesaemia14.04.02.001--
Hyponatraemia14.05.04.002--
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.002--
IIIrd nerve paralysis06.05.02.011; 17.04.02.003---
Infection11.01.08.002---
Infertility21.03.02.001---
Injection site abscess08.02.03.021; 11.01.08.023; 12.07.03.021---
Injection site haemorrhage08.02.03.005; 12.07.03.005; 24.07.01.010---
Injection site infection08.02.03.019; 11.01.08.005; 12.07.03.008---
Injection site inflammation08.02.03.008; 12.07.03.009---
Injection site pain08.02.03.010; 12.07.03.011---
Injection site phlebitis08.02.03.011; 12.07.03.012; 24.12.03.003---
Injection site reaction08.02.03.014; 12.07.03.015--
Injection site thrombosis08.02.03.028; 12.07.03.028; 24.01.01.023---
Insomnia17.15.03.002; 19.02.01.002--
Intestinal ulcer07.04.06.003---
Intracranial pressure increased17.07.02.002---
Irritability08.01.03.011; 19.04.02.013--
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Jaundice cholestatic09.01.01.005---
Laboratory test abnormal13.18.01.001---
Leukopenia01.02.02.001---
Libido decreased19.08.03.001; 21.03.02.005--
Liver function test abnormal13.03.04.030---
Lower respiratory tract infection11.01.09.002; 22.07.01.002---
Lymphadenopathy01.09.01.002---
Malaise08.01.01.003--
Mania19.16.02.002--
Melaena07.12.02.004; 24.07.02.013---
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene